Mutations in HIV-1 gag and pol
Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Prague, Czech Republic a S uccessful highly active antiviral therapy (HAART) is often hampered by the occurrence of drug-resistant viruses, leading to treatment failure. In the past, the transmission of drug-resistant viruses, which can sometimes persist even without the selective pressure of HAART, was becoming increasingly frequent (9, 20) . Nowadays, several studies show a decline in the transmission of drug-resistant variants in the western world to approximately 10% (2, 14) , whereas other studies still report stable transmission rates for certain resistance-associated mutations (RAMs) (5, 45) . The key to an effective treatment regimen relies on both the genetic barrier to resistance to a specific drug and on the ability of antiviral drugs to decrease viral load. Since treatment with protease inhibitors (PIs) reduced viral load up to 5 log steps (33) , the introduction of PIs in the 1990s paved the way for HAART and HIV protease (PR) has become a major target for therapy.
The viral PR is required for processing of both Gag and GagPol precursor proteins. This maturation step is required for viral infectivity, and PR inhibition or genetic inactivation results in noninfectious viral particles. The development of drug resistance has been well documented for HIV-1 subtype B viruses. It has been shown that treatment with certain PIs primarily selects viral species with genes encoding mutations that confer resistance (22) . These mutations directly affect the affinity of the inhibitor by changing amino acid residues in the substrate binding pocket. Since the binding pocket is optimized to bind natural substrates, changes mediating drug resistance can impair the cleavage of natural substrates and thereby affect viral fitness. A large number of X-ray structures of resistant HIV PR species have been determined (32, 43) . Most of these structures suggest that inhibitor binding by these mutated enzymes is impaired by loss or gain of van der Waals interactions between the inhibitor and the binding site pocket. Newer PIs, like darunavir (DRV), have been designed to bind to the mutated active cleft of these resistant PR species (32) . For the virus to acquire resistance against these high genetic barrier inhibitors and to compensate for losses in viral fitness, it needs to accumulate mutations resulting in up to 20 amino acid changes within its PR coding region (32) . These highly mutated PR species show a decrease in inhibitor affinity of several orders of magnitude. However, at the same time, their ability to cleave the Gag-Pol polyprotein is severely impaired, and consequently, the viral fitness is decreased. In order to counteract this, viruses acquire additional mutations within or outside the PR coding region that compensate for the loss of viral fitness by enhancing the ability of the mutated PR to cleave their substrates. These compensatory mutations have only marginal effects on inhibitor binding, but they increase the viral fitness. Some of these mutations have been identified in the vicinity of the Gag proteolytic cleavage sites, leading to improved processing of Gag by highly mutated PR. The sequence of events leading to the accumulation of resistance and compensatory mutations has been described in detail for certain PIs (7, 16, 27, 37) . Nowadays, resistance profiles are analyzed by genotypic methods, which allow an estimation of drug resistance by analyzing viral sequences. The interpretation of the sequence data is performed by expert bioinformatics systems that rely on one hand on biochemical and cell culture-derived resistance data and on the other hand on the correlation between genotypes and clinical response (11, 28) . However, new and uncharacterized mutations with unknown viral phenotypes cannot be predicted by such bioinformatics analyses alone. In addition, it is difficult to obtain reliable data on viral infectivity of highly mutated viruses using patient-derived coding sequences in reference viral backbones, since the compensatory mutations in highly mutated PRs are not sufficient to regain viral titers high enough to analyze their replication in a reliable way in cell cultures and need to be accompanied by other mutations outside the PR coding region. Furthermore, the molecular mechanisms of resistance development involving mutations outside the PR region are not fully understood. Indeed, a new resistance mechanism, where mutations in Gag conferred PI resistance prior to any changes in the PR sequence itself, has been reported (27) . This would lead to therapeutic failure without detection in the standard genotypic systems. However, PI resistance outside the PR region was reported in a single study only, and the general clinical impact so far remains unclear.
In this report, we analyze a patient-derived HIV PR sequence with a high number of mutations. Using structural and biochemical analyses, we explain the observed phenotype, i.e., resistance to most anti-PR regimens used in the treatment history of the patient. In addition, we provide evidence that the loss in viral fitness of highly mutated PRs can be rescued by autologous viral sequences of the Gag and Pol region.
MATERIALS AND METHODS
Plasmids, transfections, and titer determination. The proviral pNL4-3, pNL4-3XC, and pBD6-15 HIV plasmids were used for virus production and cloning purposes (1, 22, 34) . For heterologous expression of PR in a bacterial host, pET24 vector (Novagen) was used, and pCRII, pCR-XL, and pCR2.1 vectors (Invitrogen) were used for cloning of subgenomic HIV fragments.
The PR sequence was introduced into the pNL4-3 backbone by first inserting single XbaI and ClaI restriction sites located directly at the 5= and 3= ends of the PR coding sequence of NL4-3XC by exchanging the ApaIAgeI fragment. Subsequently, the patient-derived PR sequence was amplified by PCR and inserted into these sites. A detailed description of all clones can be found in the supplemental material.
Viruses were produced by transfection of HEK 293T cells with proviral plasmids pBD6-15 and pNL4-3 and derivatives thereof using either Turbofect (Fermentas) or FugeneHD (Roche) according to the manufacturer's instructions. Viral titers were determined on TZM-bl cells in singlecycle infections by serial dilutions of the cell culture supernatants as previously described (6) . Briefly, cell culture supernatants were collected, centrifuged (1,500 rpm, 5 min) to remove infected cells, and titrated in serial dilutions on TZM-bl cells (96-well plate, 10 4 cells per well). TZM-bl cells carry a stably integrated copy of an HIV long terminal repeat (LTR) promoter driving a lacZ gene. Two days postinfection, TZM-bl cells were fixed with ice-cold methanol-acetone for 5 min followed by a ␤-galactosidase stain, using 5-bromo-4-chloro-3-indolyl-␤-D-galactopyranoside (X-Gal) as the substrate. Stained cells were counted, and the viral titers were calculated.
Genotypic analysis, viral load determination, and reverse transcriptase PCR (RT-PCR) amplifications. Viral loads were measured with the Roche Cobas AmpliScreen and TaqMan HIV-1 test. Genotypic analyses were performed using an in-house system, and since 2000, the ViroSeq system (Abbott) has been used. The HIV-1 PR coding regions from patients were amplified and analyzed using the ViroSeq system or patientspecific primers. Amino acid substitutions with respect to the HIV sequence database consensus B sequence were analyzed with the Stanford University HIV Drug Resistance Database (http://hivdb.stanford.edu). The consensus PR CRF_02AG sequence was determined by the alignments of all 3,446 HIV CRF_02AG sequences stored in the HIV Sequence Database (http://www.hiv.lanl.gov) using mpi-clustalW (19) .
PR expression, purification, and biochemical analysis. The amplified PR coding region was cloned into the pET24a (Novagen) vector, overexpressed in Escherichia coli BL21(DE3)RIL, and purified from inclusion bodies as previously described (31) . After refolding and purification, PR was active site titrated to quantify the active enzyme in the preparation (typically, 80 to 90% of the total protein).
PR kinetic parameters (K m and k cat ) and inhibition constants for inhibitors (K i ) were determined spectrophotometrically based on the decrease in absorbance at 305 nm upon cleavage of the chromogenic peptide substrate KARVNle*NphEANle-NH2, as previously described (29, 43) . Typically, 8 pmol of PR was added to 1 ml of 0.1 M sodium acetate buffer, pH 4.7, containing 0.3 M NaCl, 4 mM EDTA, substrate at a concentration near the K m of the enzyme, and various concentrations of inhibitor dissolved in dimethyl sulfoxide (DMSO). The DMSO concentration was kept below 2.5% (vol/vol). The data were analyzed using the equation for competitive inhibition according to Williams and Morrison (44) .
The kinetics of hydrolysis of peptides corresponding to the processing sites was performed in 50 mM morpholineethanesulfonic acid (MES), pH 6.0, containing 0.3 M NaCl using 200 M peptide and 75 to 500 nM HIV PR. The reaction mixture was incubated at 37°C for 15 min to 90 min. The reactions were stopped by the addition of formic acid to a final concentration of 20% (vol/vol). Five microliters of this mixture was subsequently injected into a Zorbac SB-C 18 reversed-phase chromatography column (Agilent), and peptides were resolved using a water-acetonitrile gradient on a high-performance liquid chromatograph (HPLC) (Agilent). The peptide cleavage was monitored at 210 nm.
Crystal structure determination. Crystals of the PR-DRV complex were grown by the hanging drop vapor diffusion technique at 19°C with 0.6 M ammonium sulfate (pH 5.25) as the precipitant. Diffraction data were collected at beamline 19BM at the Advanced Photon Source, Argonne National Laboratory, IL. Data were processed using the HKL-3000 program (23) , and the crystal structure was solved by molecular replacement using the program Molrep (38) and the structure of wildtype PR (Protein Data Bank [PDB] code 1U8G [4a] ). Model refinement was carried out with the program REFMAC 5.2 (24) interspersed with manual adjustments using Coot (10) . Additional experimental details are given in supplemental materials. Atomic coordinates and experimental structure factors have been deposited in the Protein Data Bank with the code 3T3C. Data collection and refinement statistics are given in Table S2 in the supplemental material.
Nucleotide sequence accession number. The nucleotide sequences of patient-derived gag and pol were submitted to GenBank (accession no. JQ982505). (Fig. 1) . The sequence analysis of several independent clones showed that all these clones contained the mutations observed in the pool sequencing (Table 1; Table S1 in the supplemental material). Sequence comparison of the patientderived sequence with subtype AG sequences showed that 38 amino acid residues in the RT coding region were changed (see the supplemental material). The stable maintenance of the highly mutated genotype over extended periods of time under HAART and the high viral loads showed that this virus replicated efficiently under drug selection pressure. Changes of the therapy regimen did not lead to loss of accumulated RAMs in PR. This indicates that they were compatible with efficient virus replication even in the absence of full selective pressure.
RESULTS

Genotypic
PR resistance analysis. Since complex mutation patterns are difficult for expert systems to analyze, we decided to analyze the drug resistance in vitro. The PR coding region of the patient-derived virus was amplified from patient plasma (sampling date June 2004 [ Fig. 1]) , and PCR products were cloned. Sequence analysis revealed that all clones contained amino acid substitutions shown in Table 1 (T4S, L10V, I13A, K14R, K20I, A22V, L33I, E35D,  M36I, N37D, R41K, K43S, G48A, I54V, I66F, H69K, T74S, V82A,  I84V , L89I, L90M, and T91S) with the exception of one clone showing the change to 90T instead of 90M and one clone having an additional 71V mutation. These three PR coding sequences were cloned into the proviral HIV-1 B-type plasmid pNL4-3 to yield pNL4-3SA-90M, pNL4-3SA-90T, and pNL4-3SA-71V (21). These plasmids carried genes that encoded patient-derived sequences, including the complete p6pol-PR region and the first 16 amino acid residues of RT, thus also containing the cleavage sites (CSs) upstream and downstream of PR. Therefore, effects of the adaptation of PR to the CS in the p6pol-PR CS sequences on viral infectivity can be excluded (see below). HEK 293T cells were transfected with these proviral plasmids, and viral titers were determined on TZM-bl indicator cells 2 days after transfection ( Fig.  2A) . The virus derived from pNL4-3SA-90T exhibited no infectivity, while the titers of the other two recombinant viruses were reduced by approximately 3 orders of magnitude compared to wild-type HIV-1 subtype B (Fig. 2A) . Western blotting of the concentrated viruses in cells using a p24-specific antiserum revealed impaired Gag processing for pNL4-3SA-71V and pNL4-3SA-90M (Fig. 2B) , while virtually no Gag processing was observed for pNL4-3SA-90T (data not shown). Therefore, the latter construct was not included in further analyses. While Gag in wild-type viruses and transfected cells was largely processed to CA, significant amounts of processing intermediates (MA-CA and CA-SP1) were detected in the case of recombinants pNL4-3SA-90M and pNL4-3SA-71V (Fig. 2B) . CA was undetectable in the cells transfected with these recombinant clones (Fig. 2B) .
Biochemical analysis of highly mutated PR. To further characterize the highly mutated PR, the DNA encoding PR from the (17) . This PR species contains 19 amino acid changes in comparison to the CRF02_AG consensus sequence and is identical to the PR sequence described for pNL4-3SA-90M above. PR activity was measured by analyzing the cleavage of a chromogenic peptide substrate. The patient-derived PR showed in vitro kinetic values (K m ϭ 106 Ϯ 10 M; k cat ϭ 3.0 Ϯ 0.1 s Ϫ1 ) corresponding to only 1.4% of the wild-type PR specific activity. This low processivity was likely the cause for the impaired replication of the recombinant viruses derived from pNL4-3SA-90M.
Inhibition constants were analyzed by using a chromogenic substrate peptide and the indicated PIs (Table 2) . A very high relative resistance was obtained for saquinavir (SQV) (190,000-fold), ritonavir (RTV) (13,000-fold), indinavir (IDV) (7,200-fold), atazanavir (ATV) (3,900-fold), and nelfinavir (NFV) (3,600-fold). There was also substantial resistance against lopinavir (LPV) (870-fold) and amprenavir (APV) (77-fold), while resistance was much less prominent against darunavir (DRV) (11-fold) . No cross-resistance against tipranavir (TPV) was observed ( Table 2) . We also determined the relative vitality [defined as v ϭ WT where v is vitality and the K i k cat /K m ratios for the mutant (MUT) and for the wild type (WT) are shown] of the recombinant PR, which defines the relative ability of the mutated PR to process the substrate in the presence of a specific PI (Fig. 2C ). This showed a very high vitality in the presence of most PIs, again confirming that the patient-derived PR was highly insensitive to most PIs available at the time of treatment. Crystal structure. Since the patient-derived PR sequence was highly divergent from most sequences observed thus far, we set out to perform an X-ray analysis in order to determine its molecular structure. Cocrystallization was attempted with several PIs, but diffracting crystals were obtained only for DRV, which had a K i value of 59 pM ( Table 2 ). The crystal structure in complex with DRV was determined at 2.1-Å resolution and represents the first structure of a CRF02_AG PR. Interestingly, the complex crystallized in a tetragonal crystal form, which was unique among more than 400 HIV PR structures deposited in PDB. The asymmetric unit contained one HIV PR dimer with one molecule of DRV bound in the active site (Fig. 3A) .
Comparison of our patient-derived PR structure with the structure of the wild-type PR in complex with DRV (PDB code 1T3R [15] ) revealed some differences in protein structure ( Fig. 3B  and C) ; the root mean square deviation (RMSD) for superposition of all carbons at the alpha position (C-␣) in the PR dimer is 1.16 Å (Fig. 3B and C) . Detailed analysis of the RMSDs of the individual carbon positions after superimposition of the uncovered regions of the two structures with substantial local structural changes (RMSD over 1.0 Å [Fig. 3C]) . The most prominent structural changes (RMSD over 4 Å [ Fig. 3C]) were detected in residues 34 to 43, the so-called flap elbow region. This region comprises 6 amino acid changes, two of them being mutations associated with resistance (L33I and M36I). Association of four additional mutations (at positions 35, 36, 41, and 43) with resistance was not shown, except for insertion in position 35 (E35EE), which was recently reported as a novel mechanism in resistance development (17) . The flap region represents a functionally important part of the enzyme whose movement is crucial during substrate binding and release. Binding of an antibody in this region resulted in considerable enzyme inhibition with K i values in the nanomolar range (3, 18) . Mutations in the flap elbow are thus likely to affect enzymatic activity. Additional structural differences in the vicinity of the active site are located in the substrate binding site loop 79-80 (loop at positions 79 and 80), which moves closer toward the substrate binding site cavity. This structural rearrangement is caused by RAMs V82A and I84V, in which smaller side chains replace two bulky ones, and by the G48A mutation in the neighboring flap region.
Mutation T4S introduces structural changes to the dimeric interface. Regions 16-20 (region from positions 16 to 20) and 66-69 showed considerable structural changes compared to the wild type and are surface loops, which are exposed to solvent and inherently flexible.
Mutations in gag and pol are required to rescue viral infectivity. Several reports suggest a possible coevolution of PRs and cleavage sites. Therefore, we hypothesized that modified CSs could explain the strongly reduced infectivity of the pNL4-3SA-90M viruses. The complete gag and pol genes were amplified from the patient's plasma virus in order to determine the CSs in both gag and pol by nucleotide sequencing. The resulting amplicons were cloned, and three independent clones were sequenced (Table 3 ). In addition, direct amplification and pool sequencing verified all CS sequences. In contrast to our expectations, the amino acid sequences of the CSs were well conserved compared to CRF02_AG. The CS sequences in the pol gene were mostly unaltered. Differences were mainly observed in the P6pol-PR and SP1-NC CS sequences. The altered p6pol-PR CS cannot be responsible for rescue of viral replication, since this sequence was already introduced into the recombinant virus together with the PR sequence.
Since the patient-derived virus was grouped as circulating recombinant form 02_AG, we analyzed whether the subtype of the viral backbone would influence the infectivity of viruses with genes encoding the patient-derived PR. To study the influence of the viral subtype backbone and of the patient-derived Gag and Pol proteins on viral infectivity, the complete gag and pol genes were amplified from the patient-derived plasma sample (sampled on ) for the positions of the atoms in the main chain for individual residues after superposition of patient-derived structure to the wild-type enzyme (PDB code 1T3R). The RMSD is shown on the y axis. Mutated residues are highlighted in red and green for RAMs and non-RAMs, respectively. RMSDs greater than 0.7 Å were considered to be significant (4).
November 2004 [ Table 1 ]). The patient-derived PR sequence in this case was identical to the PR sequence of pNL4-3SA-71V, with the exception of two amino acid changes, L10V to L10I and L89I to L89V. We then inserted the patient-derived PR sequence into the pBD6-15 infectious CRF02_AG proviral plasmid, yielding pBD6-15PR. HEK 293T cells were transfected with this proviral plasmid, and viral infectivity was analyzed in comparison with wild-type HIV-1 subtype B and CRF02_AG (Fig. 4B, PR) . Infectivity was reduced by more than 1 order of magnitude compared to the cognate strain and by almost 2 orders of magnitude compared to the B-type virus.
To determine whether additional changes in gag or pol could compensate for the fitness loss due to PR mutations, we introduced different regions from the patient-derived amplicons into pBD6-15PR and analyzed their respective infectivity (Fig. 4A and B). Inserting the entire region from the 3= end of the CA coding region to the 5= end of the IN coding region almost completely rescued viral infectivity (Fig. 4, 3=CA-IN) . This fragment contains all CSs in Gag and Pol except for the MA/CA site. The effect appears to be due to additive compensatory changes upstream and downstream of PR, since inserting the region from the 3= end of CA until PR as well as inserting the region from PR to the 5= end of IN led to a partial rescue. Most compensatory mutations in gag so far mapped to the 3= coding region, including the NC/SP2 and SP2/p6 CS. However, inserting these regions into pBD6-15PR did not compensate for the loss of infectivity, clearly indicating that additional changes in the upstream parts of both Gag and Pol are needed to achieve full rescue of infectivity. Given that the upstream and downstream CSs are conserved between the patientderived sequence and wild-type CRF02_AG, these compensatory mutations must map to sequences outside the immediate PR recognition motifs.
Mutations in the p6pol-PR and SP1-NC cleavage site enhance cleavage efficiency. In order to analyze the direct influence of the amino acid changes in the cleavage sites, in vitro protease assays were performed. Peptide substrates representing the sequences of SP1-NC and NC-SP2 and the p6pol-PR cleavage sites of the subtype B, CRF02_AG, and of the patient-derived sequence were assayed with the subtype B, AG, and patient-derived proteases. The relative efficiency of cleavage was determined using HPLC separation of the cleavage product (Fig. 5) . For all of the analyzed cleavage sites, the patient-derived PR was shown to be the superior enzyme. The most significant improvement of the relative hydrolysis efficiency could be seen in the case of the p6pol/PR peptide: the patient-derived PR cleaves the mutated peptide sequence by 1 order of magnitude more effectively than the wild-type (wt) sequence. The relative preference of individual PRs has shifted for all substrates analyzed, suggesting a change in the substrate specificity of the patient-derived PR.
DISCUSSION
In this report, we present well-documented data on a specific case of pediatric HAART failure, which ultimately led to one of the highest accumulation of RAMs in the PR coding sequence observed thus far. Despite the major success of HAART in the longterm survival of HIV-infected patients, adherence and the development of drug-resistant viruses remains problematic (35) . Therapy failure often results in the accumulation of RAMs and causes multidrug resistance. Monitoring a patient's CD4 ϩ T-cell count and viral load has been the standard practice to monitor a patient's health status while infected with HIV/AIDS (36) . Early analysis of our patient (when he was 4 years old) showed that he had a nonexistent CD4 ϩ T-cell count, indicating a failure to control HIV and profound immune suppression. The long-term survival and the ability of this patient to conquer further infections, despite his low CD4 ϩ T-cell count and high viral load, remain inexplicable. Since the end of 2008, when he was 16 years old, with the treatment change to DRV, ETR, and raltegravir (RAL), his CD4 ϩ T-cell count has significantly increased, and his health status has improved. A genotypic assay prior to the treatment change had shown that the patient-derived virus was susceptible to RAL and ETR, but already showed low-level resistance to DRV due to the I84V and L89V amino acid changes. On the other hand, the positive clinical development indicates that the treatment regimens based on advanced antiviral regimens offer a promising option even to patients where all previous treatment options have failed.
We have been monitoring the viral evolution of the PR coding region under therapeutic pressure for more than 10 years. We observed the development of genotypes with various RAMs, which ultimately led to a strain resistant to almost all currently available PIs. During this period of time, as many as 19 amino acid changes accumulated in the PR region, while the resistant virus replicated at high levels (Fig. 1) . In addition to 11 mutations known to be associated with resistance, there were eight mutations of unknown function in the protease. It is likely that some of these mutations compensate for the decrease in viral fitness caused by the RAMs in this hypermutated protease.
During our in-depth analysis of virus isolates derived from this patient, we observed the tremendous flexibility of viral sequences. The number of mutations found far exceeded the rate of substitutions observed in other HIV lineages. This was true not only for RAMs but for other mutations as well. It has been reported that viruses with such a high number of genetic mutations usually have lower fitness levels both in vitro and in vivo (12, 42) . However, in this case, an actively replicating virus with a high viral load in vivo despite HAART was observed. Therefore, we assumed that the viral PR is active, despite having such a high number of unusual mutations.
We have analyzed changes in RAMs in this patient after treatment changes. Only the change from LPV to DRV resulted in a change in RAMs. The type of RAMs lost after the treatment regimen change was surprising, since it could have been expected that mutations with a high impact on viral fitness (like L90M) would disappear first. Instead, minor resistance mutations such as A71V and L89V reverted. The maintenance of the L90M mutation is especially curious, since this mutation was the only one to disappear during the treatment interruption in 2002. The results of analyses of synonymous mutations and of changes in the genotype after treatment modifications indicate that the highly mutated viral genotype was surprisingly stable. This is in contrast to our expectation, since highly mutated viruses are supposed to have a replication disadvantage, but it is in line with the high replication capacity of the virus in the patient. The introduction of the patient-derived gag and pol sequences showed that both regions could independently improve the replication capacity of the virus to reach wild-type levels in vitro.
The large number of non-RAMs could be explained if they could somehow influence viral fitness, which was not analyzed during this study. Gag fragments, including p2, did rescue infectivity with the patient PR, showing that the viral Gag and Pol sequences have coevolved and that selective pressure of the PR led to adapted gag and pol sequences. Even more surprising was the fact that the pol sequences were required for the rescue of viral fitness, since the RT sequence encodes 12 RAMs and 21 additional substitutions compared to the corresponding CRF02_AG consensus sequence. The contribution of each amino acid change to the rescue has yet to be analyzed.
The crystal structure of patient-derived PR revealed a substantial rearrangement in the flap structure, and thus, we can expect changes in the substrate, inhibitor binding, and release. Nevertheless, it is very difficult to dissect the roles of 19 individual substitutions in resistance development. Mutations V82A and I84V in the active site of the enzyme cause structural changes in the socalled 79-80 loop, which is part of the S1/S1= subsites and thus directly affects the binding affinity of some inhibitors. This structural rearrangement has been reported previously (30) . However, in our structure, the mutation G48A further contributes to the collapse of the 79-80 loop toward the center of the active site. Mutations outside the substrate binding cleft can compensate for the enzyme activity decreased by primary mutations, or they can also contribute to resistance by provoking long-range structural changes in the active site and affecting dimer stability and inhibitor binding kinetics (25, 41) .
This report demonstrates a way to analyze phenotypes of highly resistant HIV-1 clones, which is normally hampered by the low replicative fitness of such clones. The first rule in a phenotypic assay of resistant HIV-1 clones is that the authentic subtype backbone is required. This seems obvious but is rarely fulfilled. We show here that non-B subtype viral background sequences may improve fitness in proviral clones of the same subtype. The expanding range of proviral clones from non-B subtypes will provide a basis for better phenotypic analysis. Furthermore, previous reports highlighted the importance of compensatory mutations in the PR region (7, 16, 40) . In addition, we show here that for proper evaluation of viral fitness, autologous gag and pol sequences are required. In this case, the introduction of those sequences led to a replication level like that of the wt virus. This virus reflected the in vivo clinical situation, since it replicated at high levels in the patient. Recently published mutations in Gag that supported resistance and viral fitness were not found in the patient-derived sequences described here (40). This could be explained either by major differences in the corresponding PR sequences or by the fact that the virus analyzed in this report does not belong to the B subtype.
It has been reported that amino acid changes in the PR region are correlated with changes in CSs (8, 13, 16, 26, 27, 39) . None of the CS mutations found matched the previously published mutations. We cannot rule out the possibility that the mutations in the p6pol-PR CSs are important for the PR activation, but introduction of all other CS mutations did not lead to significant increases in virus titers. Therefore, a strong correlation of PR RAMs with CS mutations was not observed. On the other hand, the mutations that did accumulate in the vicinity of the processing sites spanning the p2/NC, NC/p1, and p6pol/PR proteins lead to much more efficient hydrolysis of corresponding peptides by patient-derived PR compared to the wild-type enzyme. The patient-derived PR processed the p2/NC peptides more effectively than the consensus B type or CRF02_AG PRs, suggesting a change in the substrate specificity of the patient-derived PR. The most significant was the improvement of the cleavage of the peptides spanning the p6pol/PR boundary: such an effective processing at this site might improve the activation of the PR from the Gag-Pol polyprotein and thereby improve viral fitness of the patient-derived virus. This substrate-enzyme coevolution might thus explain high titers of the virus under the constant pressure of antiviral agents.
Our analysis demonstrated that the evolution of complex drug resistance can give rise to coadapted sets of mutations that are stable (have low tendency to revert) and that enable virus replication to near wild-type virus levels. Although highly mutated genotypes are still rarely observed and we describe a single case, the replication to near wt virus levels might imply a high transmission potential and might pose a greatly increased risk for the epidemic spread of HIV drug resistance. Such complex drug-adapted viruses should therefore be monitored with extreme care, and tailored therapy should be used to suppress virus loads to below transmission levels. Pediatric patients, with inherently weak immunity and a high level of CD4 ϩ T-cell production might provide a particularly permissive environment for the evolution of complex adaptations in HIV. On the other hand, therapy with DRV, RAL, and ETR suppressed viral replication efficiently, which indicates that treatment with new antiviral drugs might lead to the effective suppression of viral transmission and further evolution.
